Join us for Quality Bites 2019 – A Digital Compliance Conference. Learn More

Request a Proposal  

Pharm-Olam Blog

Pharm-Olam Insights Blog

Pharm-Olam is a global CRO dedicated to helping you create a healthier world through the development of life-changing treatments. Here on our blog we will share our insights from recent studies, to interviews with industry leaders, investigators and patients.

Blog Feature

Pharm-Olam Insights | Pattern of Excellence

By: John Barry
September 12th, 2019

In this post, we hear from Pharm-Olam's Chief Operations Officer, John Barry, and how he walked the Pattern of Excellence and described the value of it to a prospective customer.   Sponsors are looking for CROs to provide more value and to more clearly differentiate themselves.  This in part is why Pharm-Olam established its Pattern of Excellence.  Through John's story, you may learn how the Pattern of Excellence could apply to you and your next study, with Pharm-Olam as your CRO partner.  

Blog Feature

Rare & Orphan Disease

By: John W Colby III
August 13th, 2019

When working on a rare disease program, there are far reaching benefits to conducting a natural history (NH) study. In this article, Pharm-Olam's Dr. Jovana Vlajkovic-Josic was interviewed by Melissa Fassbender from Outsourcing-Pharma.

GDPR_Checklist-cover

Join other Clinical Development experts to get the latest industry news, trends and insights.

As a thank you for subscribing, you'll receive a free copy of our GDPR Controller & Processor Checklist

Blog Feature

GDPR

By: Natasa Spasic
July 29th, 2019

Personal data privacy has taken another evolutionary step with the release of the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons, the General Data Protection Regulation (GDPR).  If you work for an organization that is not based in the EU, you may or may not be aware of the GDPR.  The GDPR, came into effect on May 25, 2018. 

Blog Feature

Rare & Orphan Disease

Pharm-Olam specializes in the conduct of complex global rare disease clinical trials. Because Phase 3 trials are designed to assess the efficacy, effectiveness, as well as safety of a new drug, this is typically a difficult, costly and time-intensive process. The difficulty of Phase 3 trials rachets up even more when it is conducted in a rare disease population.

Blog Feature

Pharm-Olam Insights

By: Sharon Powell
July 29th, 2019

Your clinical trial has been running for years potentially and now it is time to achieve a database lock that is efficient, quality driven and on time.  A critical component to the overall success of any clinical trial is how Clinical Data Management (CDM) manages the trial during its conduct and how it closes it out to achieve database lock.